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compare the effectiveness with CAS and CEA in 677 patients with symptomatic 
carotid artery stenosis in korean clinical practice. Methods: From January 1 2008 
to December 31 2011, retrospective cohort study was conducted in 677 symptomatic 
carotid stenosis patients with more than 50% stenosis) (CAS= 346, CEA= 331) in the 
Korean hospitals (Asan medical center, Samsung medical center, Severance hospital, 
Inha university hospital, Chonnam university hospital). The primary outcome was 
stroke, myocardial infarction, or death during periprocedural (30-day) and postproce-
dural period. Results: For 677 patients over 2-year follow-up period, All death, major 
stroke, minor stroke were higher in CAS group than CEA (1.45% vs. 0.30%, 4.05% vs. 
1.81%, 3.47% vs. 3.02%, 0.58% vs. 0%). All outcomes were higher in CAS than in CEA 
within 30-day after treatment and in subsequent years, except the incidence of 30 
days-minor stroke. ConClusions: CEA was superior to CAS in symptomatic patients 
with carotid stenosis. This study suggests that CEA can be considered the first-line 
therapy for symptomatic carotid artery stenosis in South Korea.
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objeCtives: For patients with uncontrolled hypertension, differentiation of phar-
macological resistance from inadequate or improper medication use is key to clini-
cal management. Proteus Digital Health has developed a unique digital feedback 
system, which utilizes an Ingestible Sensor (IS) to determine medication-taking 
patterns. A wearable sensor in the form of an adhesive patch collects timing and 
taking of IS ingestions, and physiological and behavioral metrics such as heart 
rate, and patterns of activity and rest, providing insights into the patient’s day-
to-day lifestyle. This study evaluates the utility of the Proteus system in patients 
with uncontrolled hypertension. Methods: Patients with a history of uncontrolled 
hypertension (BP> 140/90) at 5 primary care centers in the United Kingdom were 
prescribed the Proteus system for 14 days. Patients co-ingested the IS along with 
their prescribed BP medications while simultaneously wearing the patch. BP was 
measured on days 1 and 14 by a clinician, and all other parameters, such as adher-
ence, activity and rest patterns, were collected via the Proteus system. Results: 
Of the 190 patients, 21 patients had incomplete data. In the remaining 169 patients 
(89%), mean medication adherence was 88%, and mean BP decrease was -7.6 mm 
Hg systolic and -3.8 mm Hg diastolic. The system data provided diagnostic insight 
differentiating non-response vs. non-adherence. One hundred forty-eight (78%) 
patients had ≥ 70% adherence; 100 (53%) achieved blood pressure control on their 
prescribed therapy, and 48 (25%) remained uncontrolled and required modifica-
tion of their therapeutic regimen. The remaining 21 patients (11%) were identi-
fied as needing intervention to support medication adherence. ConClusions: In 
patients with a history of uncontrolled hypertension, 53% achieved BP control within 
2 weeks, and 25% received an informed therapeutic intervention using the Proteus 
system. Thus, Proteus can identify specific individual needs for progressing through 
the recommended treatment pathway and for advancing toward treatment goals.
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objeCtives: Randomized controlled trials (RCTs) provide the most robust evi-
dence source for making patient health care decisions. When RCT data are lacking, 
however, complementary evidence sources may also be needed. As an example of 
this, three clinical trials comparing rosuvastatin with atorvastatin were simulated 
using the Archimedes model, a validated, individual-based simulation of human 
pathophysiology and behaviours, treatment interventions and health care sys-
tems. Methods: Comparison A assessed clinical outcomes in patients receiving 
available doses of the two drugs. Comparison B assessed the impact of initial treat-
ment decisions, with individuals randomized to receive various doses of either 
rosuvastatin or atorvastatin and eligible for treatment intensification for up to 5 
years if target lipid levels were not met. Comparison C assessed the effect of switch-
ing patients’ treatment from rosuvastatin to atorvastatin. Results: In comparison 
A, rosuvastatin was estimated to result in greater reductions than atorvastatin 
in major adverse cardiac events (MACEs) at 5 and 20 years at all doses examined 
(relative risk [RR]: 0.907,0. 892 and 0.931 at 20 years for rosuvastatin 20 mg versus 
atorvastatin 40 mg, rosuvastatin 40 mg versus atorvastatin 80 mg, and rosuvastatin 
20 mg versus atorvastatin 80 mg, respectively; P< 0.05 in all cases). In comparison 
B, outcomes were significantly better in patients initially prescribed rosuvastatin 
relative to atorvastatin (RR of MACE at 10 years: 0.919; P< 0.001). In comparison C, 
risk of MACE was significantly greater in patients who switched from rosuvastatin to 
atorvastatin, relative to those who remained on rosuvastatin (RR at 10 years: 1.115; 
P< 0.001). ConClusions: In this example using the well-validated Archimedes 
model, better outcomes were predicted in patients receiving rosuvastatin than 
in those receiving atorvastatin in a variety of different settings. This provides an 
example of the utility of robust modelling approaches to generating evidence that 
is not available from clinical trials.
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stances. All 3 economic studies found MIS in the treatment of ICH was associated 
with lower costs compared to MM or CR. In one study MIS resulted in a $USD44,329 
saving in acute care costs compared to MM, primarily driven by lower hospital bed 
days (70 vs. 98.9 days). ConClusions And iMPliCAtions oF KeY FindinGs: MIS 
in the treatment of ICH presents convincing evidence for improved efficacy over MM 
and CR. The latest clinical practice guidelines for the treatment of ICH do not yet accu-
rately reflect these latest findings and as such, current treatment practices may be 
lagging behind what the highest level of evidence suggests should be standard of care.
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objeCtives: One reason of the low efficiency of cardiovascular diseases (CVD) 
treatment in Ukraine is the low adherence of patients. Modern trends improving 
the quality of treatment and increase patients compliance is use of polypills (PP). 
The aim: pharmacoeconomic assesment the feasibility of PP amlodipine and ator-
vastatin versus monodrugs in patients with hypertension and dyslipidemia (DYS) 
from the Ukrainian perspectives point of view. Methods: The results of clinical 
studies AVALON (Granger C. B., McMurray J. J., Yusuf S. et al., 2003) were used. Cost 
minimization analysis of three regimens of patients treatment with hypertension 
and DYS during 8 weeks: PP amlodipine 5 mg + atorvastatin 10 mg; amlodipine 5 mg; 
atorvastatin 10 mg. Results: The results of the clinical research AVALON found, 
that the use of PP amlodipine+atorvastatin provides significant clinical benefit: 
the largest number of patients reached target levels of blood pressure (BP) and 
low-density lipoprotein cholesterol (LDL-C) (45.5%), versus amlodipine (8.3%), ator-
vastatin (28.6%), placebo (3.5%). The scheme using amlodipine is the most expensive 
(cost for course of treatment (CCT) € 20.28), the regimen of atorvastatin 10 mg (CCT 
€ 10.46) and the PP amlodipine+atorvastatin (CCT € 17.72) are less costly. This PP is 
more cost effective versus amlodipine monotherapy (CER = € 38.95 versus € 244.34 
per patient with target levels of BP and LDL-C) and less cost effective compared 
atorvastatin monotherapy (CER = € 36.57 per patient with target levels of BP and 
LDL-C). The cost of an additional unit of effectiveness (ICER) showed that the use of 
PP amlodipine+atorvastatin instead amlodipine provides for the treatment of each 
100 patients additional 37.2 patients achieved target levels of BP and LDL-C and 
saving € 6.88 per patient. ConClusions: Pharmacotherapy of patients with hyper-
tension and DYS based on PP amlodipine+atorvastatin provides significant clinical 
benefit versus monodrugs and pharmacoeconomic advantages versus amlodipine.
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objeCtives: The AMPLIFY trial compared apixaban to low-molecular-weight 
heparin (LMWH) followed by a vitamin K antagonist (VKA) for treatment and 
prevention of recurrent venous thromboembolism (VTE). The AMPLIFY-EXT trial 
compared extended treatment with apixaban to placebo in previously treated 
patients. This analysis evaluated the potential lifetime implications of apixaban 
treatment versus LMWH/VKA. Methods: A Markov model was developed to eval-
uate the lifetime impact of treatment and prevention of VTE with apixaban (5 mg 
BID for 6 months, then 2.5 mg BID) versus LMWH/VKA. Clinical event rates were 
taken from AMPLIFY, AMPLIFY-EXT, and indirect treatment comparison. Length 
of stay for hospitalizations was taken from AMPLIFY for recurrent VTE (median 
5 days for apixaban, 6 days for LMWH/VKA) and major bleeds (median 5 days for 
apixaban, 7 days for LMWH/VKA). Sixty percent of patients with recurrent VTE 
and all patients with major bleeding were assumed to be hospitalized. Outcomes 
evaluated were events and hospital bed days avoided, number needed to treat to 
avoid a recurrent VTE, number needed to treat to harm with an additional bleed, 
and life years gained. Results: In a cohort of 1,000 patients, lifetime treatment 
with apixaban versus LMWH/VKA resulted in 6 fewer recurrent VTE events, 191 
fewer major bleeds, 707 fewer clinically relevant non-major bleeds, and 1,730 hos-
pital bed days avoided. On average, a patient treated with apixaban gained about 3 
months of life expectancy due to avoidance of VTE events and major bleeds. These 
results translated to one recurrent VTE event avoided for each 157 patients treated 
and one major bleed avoided for each 5 patients treated with apixaban versus 
warfarin. ConClusions: Apixaban for treatment and prevention of VTE appears 
to be a superior alternative to LMWH/VKA, leading to fewer recurrent VTEs, bleed-
ing events, and hospital bed days resulting in a projected increase in life-expec-
tancy.
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objeCtives: Carotid endarterectomy (CEA) has been recommended as the gold 
standard for the management of carotid disease in many clinical guidelines. But, 
in Korean clinical practice, carotid artery stening (CAS) was conducted more than 
CEA (21.6%) based on the national claims-data. The purpose of this study was to 
